A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe ARDS From COVID-19. Bowdish ME, Barkauskas CE, Overbey JR, Gottlieb RL, et al. Am J Respir Crit Care Med 2022 Sep 13. doi: 10.1164/rccm.202201-0157.

Read + Share

Amedeo Smart

Independent Medical Education

Bowdish ME, Barkauskas CE, Overbey JR, Gottlieb RL, et al. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe ARDS From COVID-19. Am J Respir Crit Care Med 2022 Sep 13. doi: 10.1164/rccm.202201-0157.
PMID: 36099435